Clinical Trial Update: Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A pediatric Phase 1/2 study of brentuximab vedotin (ADCETRIS) in relapsed or refractory systemic anaplastic large cell lymphoma or Hodgkin lymphoma has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Relapsed or Refractory Hodgkin Lymphoma, Relapsed or Refractory Anaplastic Large-cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-05-15